Annabel S. Alig

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis.

Anti-EGFR-based maintenance versus stop and go in patients with left-sided, non-MSI-H, RAS/BRAF-wt metastatic colorectal cancer: individual patient data pooled analysis.

Journal: ESMO open
Published: January 16, 2026

Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial.

Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: January 12, 2026

Management of mismatch repair-deficient tumors

Management of mismatch repair-deficient tumors

Journal: Innere Medizin (Heidelberg, Germany)
Published: December 02, 2025

The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients.

The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 23, 2025

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).

First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).

Journal: European journal of cancer (Oxford, England : 1990)
Published: September 11, 2025

Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 16, 2025

Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich.

Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich.

Journal: Cardio-oncology (London, England)
Published: March 31, 2025

Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.

Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 13, 2025

Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.

Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial.

Journal: EClinicalMedicine
Published: September 12, 2024

Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).

Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).

Journal: Journal of cancer research and clinical oncology
Published: July 24, 2024

Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.

Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial.

Journal: ESMO open
Published: April 04, 2024

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

Journal: ESMO open
Published: January 29, 2024
Showing 1-12 of 19

Last Updated: 09/26/2026